Compliance
How to not get your peptide merchant account shut down
A step-by-step operating playbook to keep a peptide merchant account boarded: what triggers a shutdown, the controls that prevent it, and the warning signs that mean you have days, not months.
Peptide Merchant Services — Compliance
How to not get your peptide merchant account shut down
A step-by-step operating playbook to keep a peptide merchant account boarded: what triggers a shutdown, the controls that prevent it, and the warning signs that mean you have days, not months.
Updated August 2, 2026 · 10 min read · https://peptidemerchantadvocates.com/resources/how-to-not-get-peptide-merchant-account-shut-down
The short answer
Peptide merchant accounts get shut down for four reasons: the catalog contains a product the acquirer cannot lawfully board, the website makes therapeutic claims, disputes and refunds run hot, or the account is doing something the underwriting file never disclosed. Keep the catalog lawful, the claims off the site, disputes low and documented, the disclosed profile matched to reality, and a second processor warm — and shutdowns become recoverable events instead of business-ending ones.
Why do peptide merchant accounts actually get shut down?
Almost every termination traces back to one of four causes, and none of them are random. First, catalog risk: a SKU appears that the acquirer or its sponsor bank cannot lawfully board, most often a consumer-facing or prohibited item added quietly after approval. Second, claims risk: the site starts describing outcomes — weight loss, performance, anti-aging, dosing — and the acquirer's monitoring vendor screenshots it. Third, transaction risk: disputes, refunds, or fraud signals cross the thresholds the card brands monitor. Fourth, disclosure risk: the account is processing a channel, geography, ticket size, or volume that the underwriting file never mentioned.
The reason terminations feel sudden is that none of these are evaluated on your schedule. Site monitoring runs continuously, dispute ratios are computed monthly, and portfolio reviews happen when a sponsor bank decides to run one. By the time you get the notice, the finding is usually weeks old and already documented.
Rule 1: keep the catalog boardable, SKU by SKU
Your merchant account is underwritten against a catalog, not a company. The discipline that keeps it alive is "no file, no SKU": every product has a written disposition — the lawful pathway it fits, who may buy it, which states it may ship to, and who approved it. If a SKU cannot produce that record, it does not go live on the site that the acquirer is watching.
- Maintain a SKU disposition register and review it before any product launch.
- Never add a consumer-direct or prohibited item to a site tied to a boarded MID, even temporarily.
- Treat a supplier change, a new dosage form, or a new state as a new SKU decision.
- Remove discontinued products from the live site — stale pages are still evidence to a monitoring vendor.
Rule 2: keep therapeutic claims off every surface you control
Claims are the fastest way to lose an account because they are the easiest thing for a third party to find. Monitoring vendors crawl product pages, blog posts, FAQs, meta descriptions, and increasingly social profiles and affiliate pages. A single testimonial or a before/after image on a page nobody has edited in a year is enough to open a file.
The safe posture is professional, non-promotional information: what the product is, who may lawfully buy it, and what documentation is required. No outcomes, no dosing guidance to the public, no testimonials, no influencer codes, no comparative "as effective as" language.
- Audit every indexed URL quarterly, not just the storefront.
- Include affiliates, resellers, and paid ads in the audit — their claims land on your file.
- Keep a dated claims-audit record so you can show the acquirer the control exists.
Rule 3: manage disputes before the ratio, not after
Card brands monitor dispute activity on a rolling basis, and a merchant that crosses a monitoring threshold enters a program with deadlines attached. The mechanics that keep the number down are unglamorous: a recognizable billing descriptor, responsive support with a documented refund path, delivery confirmation on every shipment, and compelling-evidence responses filed on time with the underlying documents attached.
The second half of the job is proving the work. An acquirer deciding whether to keep a merchant wants to see that disputes are being worked, not just absorbed. A monthly one-page summary of dispute volume, causes, and remediation is often the difference between a review and a termination.
- Use a descriptor customers recognize, with a working support number.
- Confirm delivery on every order and retain the record.
- Respond to every dispute with documents, even the ones you expect to lose.
- Track cause codes monthly and fix the top cause before the next cycle.
Rule 4: never let the account drift from what was disclosed
Underwriting approves a specific picture: product mix, buyer type, average ticket, monthly volume, geographies, sales channels, and fulfillment model. Growth changes that picture, and undisclosed change reads to a risk analyst exactly like concealment — even when it is entirely innocent.
The remedy is boring and effective: notify the acquirer in writing before a material change. A merchant who volunteers "we are adding a new channel next month, here is the documentation" is managed. A merchant discovered doing it is terminated.
- Disclose new product lines, channels, states, and fulfillment partners in advance.
- Flag volume or ticket increases before they land, not after.
- Keep a written record of every disclosure and the acquirer's response.
What are the warning signs an account is about to be closed?
Shutdowns are rarely the first action. The signals that precede them are recognisable if you are watching for them, and each one is a window to act.
- A request for updated documentation, a site review, or a fresh business summary.
- A reserve being introduced or increased, or settlement timing being extended.
- Individual transactions being held or reviewed manually.
- A dispute or fraud monitoring notice from a card brand.
- Silence from a previously responsive account manager.
What should you do the day the warning arrives?
Answer in writing, completely, and fast. Provide the compliance file rather than a narrative: catalog with dispositions, credentialing controls, claims audit, dispute remediation summary, fulfillment and traceability records. Fix anything the notice identifies before you reply and say what you fixed. At the same time, activate the backup processor and confirm your payout and reserve terms in the existing agreement so you know exactly what is at stake.
What does not work: escalation calls without documents, arguing the finding, or quietly removing the offending page and hoping the screenshot was not taken.
How do you make a shutdown survivable?
Redundancy is the only real insurance. A single-processor business is one decision away from zero revenue; a business with a second boarded, low-volume MID and a tested failover keeps trading while it sorts out the first relationship. Beyond the second processor, keep your own copies of processing statements, dispute records, and customer data, and know the hold period and release terms in your agreement before you need them.
If you are already frozen, the sequence is: secure funds and understand the hold, preserve records, remediate the underlying finding, then present a clean file to the next underwriter. Applying somewhere new before remediating simply reproduces the same termination a few months later.
Key takeaways
- Four causes explain nearly every shutdown: catalog, claims, disputes, undisclosed change.
- Your account is underwritten against a catalog — "no file, no SKU" keeps it boardable.
- Monitoring vendors read every indexed page, including affiliates and stale posts.
- Work disputes and document the remediation monthly; the record matters as much as the ratio.
- Disclose material changes in writing before they happen.
- Keep a second processor warm — redundancy turns a termination into an inconvenience.
Frequently asked questions
Why did my peptide merchant account get shut down without warning?
Usually the finding was not new to the acquirer even if it was new to you. Site monitoring, dispute ratio reviews, and sponsor-bank portfolio reviews run on their schedule, so the decision often reflects evidence collected weeks earlier — most commonly a prohibited catalog item, a therapeutic claim on a page you control, elevated disputes, or activity the underwriting file never disclosed.
What is the single fastest way to lose a peptide merchant account?
Publishing therapeutic or outcome claims on a site tied to the merchant ID. Claims are trivially discoverable by monitoring vendors, they implicate FTC and card-brand rules at once, and a screenshot is all the documentation an acquirer needs.
How do I keep my chargeback ratio from triggering a review?
Use a recognizable billing descriptor with working support contact, confirm delivery on every order, offer a documented refund path before a customer disputes, respond to every dispute with evidence, and track cause codes monthly so you fix the top driver rather than absorbing it.
Should I tell my processor before I add a new product or sales channel?
Yes, in writing and in advance. Undisclosed change is read as concealment during a review, while a documented advance disclosure is treated as normal account management — and it gives the acquirer a chance to tell you what would not be boardable before you build it.
Do I need a second merchant account as a backup?
If payment acceptance is essential to your revenue, yes. A second boarded processor kept warm at low volume means a termination pauses one rail instead of stopping the business, and it removes the pressure to accept bad terms in an emergency.
My account is frozen — what should I do first?
Understand the hold and release terms in your existing agreement, preserve your processing statements and dispute records, and remediate whatever triggered the action before approaching a new underwriter. Applying elsewhere with the same unresolved issue typically reproduces the termination.
Related compliance resources
More guidance on staying compliant and keeping payment processing in place.
- 10 things to know when selling BPC-157BPC-157 is one of the most searched peptides and one of the hardest to sell lawfully. Ten things every seller should understand about its regulatory status, marketing limits, and payment acceptance. 9 min read
- How to legally run a peptide company in 2026A plain-English operating model for a defensible peptide business: lawful product pathways, the right entity, restricted marketing, and an examiner-ready payments file. 9 min read
- Is it legal to sell peptides? The four lawful pathwaysSelling peptides is legal only inside one of four FDA pathways. Here is what each one (FDA-approved, 503B, 503A, and research/IND) requires — and what falls outside the law. 8 min read
- 503A vs 503B for peptides: which compounding pathway fits?The difference between 503A and 503B decides whether you can sell office stock, who can be the seller, and what you can compound. Here is the practical breakdown for peptides. 7 min read
- Why "research use only" peptides can't be sold for human useSelling RUO or "not for human consumption" peptides into the physician-to-patient channel is one of the highest-risk models in the industry. Here is why — and what the FDA has said. 6 min read
- Selling GLP-1 peptides (semaglutide, tirzepatide) legallyGLP-1 and GLP-1-adjacent peptides carry unusually high regulatory risk. Here is the hardline policy a bankable business needs — and what the FDA has said about compounding them. 7 min read
This article is general educational information about regulatory frameworks (FDA, FTC, 503A/503B, DSCSA), not legal advice. Peptide compliance turns on product-specific and state-specific facts — review your model with qualified FDA, healthcare, and payments counsel before acting.
Keep reading
9 min read
How to legally run a peptide company in 2026
A plain-English operating model for a defensible peptide business: lawful product pathways, the right entity, restricted marketing, and an examiner-ready payments file.
8 min read
Is it legal to sell peptides? The four lawful pathways
Selling peptides is legal only inside one of four FDA pathways. Here is what each one (FDA-approved, 503B, 503A, and research/IND) requires — and what falls outside the law.
7 min read
503A vs 503B for peptides: which compounding pathway fits?
The difference between 503A and 503B decides whether you can sell office stock, who can be the seller, and what you can compound. Here is the practical breakdown for peptides.
Get a free statement review — no obligation.
We review your processing statement and flag every risk indicator underwriters will ask about. Back to you within 24 hours.